NY-CLARITY-AI
Clarity AI announced today that it has closed a USD $15 million funding round led by Deutsche Börse AG and co-investor Mundi Ventures. Clarity AI empowers investors to manage the impact of their portfolios through a proprietary technology platform that leverages big data and machine learning to assess sustainability for all societal stakeholders.
“Our purpose is simple: to measure the impact of companies on our society and planet,” said Rebeca Minguela, Founder and CEO of Clarity AI. “Investors attempting to evaluate impact have faced fragmented and unreliable data, inconsistent subjective definitions, and a lack of standards and tools for comprehensive analysis. Historically it has been too hard and resource-intensive to get accurate and transparent insights. Clarity AI provides a solution for that.”
Since its founding in 2017, Clarity AI has attracted a client network representing in excess of $3 trillion of assets and funding from investors, including Kibo Ventures, Founders Fund, Seaya Ventures and Matthew Freud. The company has built the most reliable tech platform on social and environmental impact, featuring more than 30,000 companies, 198 countries, 187 local governments and over 200,000 funds. The company uses proprietary technology and algorithms to produce transparent assessments for investors that are the most consistent and comprehensive available.
The “Sustainable Investment” market has grown 34% in the last two years and now represents one third of total global assets under management (AUM) – $30.7 trillion (of a total of $79.2 trillion).1 This rapid growth comes as research shows that 81% of investors want to better understand and improve the impact performance of their investments, with millennials (in particular) demanding greater social impact transparency in their portfolios.2
In the last six months, Clarity AI has seen a significant increase in demand for its services, including signing clients with eight times the assets under management as in the preceding period.
Minguela added: “2020 has seen extraordinary volatility and uncertainty – from COVID-19 to social justice protests. It has never been more important for investors to have accurate insights on the true impact of the companies in which they place their trust and their money. That is why we are scaling up our business to enable investors to identify and support those companies helping to solve society’s biggest challenges.”
The $15 million investment will drive Clarity AI’s sustainable expansion plans, including scaling-up investment in proprietary technology and AI, as well as integrating with the world’s largest financial services platforms. This approach will make it even quicker and easier for investors and corporations to analyze and report sustainability and impact.
Deutsche Börse AG led the funding round, underscoring the strong alignment of the Clarity AI product offering with Deutsche Börse’s expanding presence in the sustainability space and the importance of accelerating the growth of a European-focused Impact and ESG technology platform. Clarity AI and Deutsche Börse are also exploring potential collaboration opportunities in various Deutsche Börse business areas, including Qontigo, a leading provider of indices and analytics.
Sebastian Ceria, CEO of Qontigo, said: “This partnership reflects our mutual commitment to the ongoing enhancement of sustainable investing and the application of the latest technology in pursuit of this goal. We were very impressed by Rebeca and her team’s vision for Clarity AI and the advanced technology platform they have created. We are excited to be in a partnership that puts impact at the heart of investment.”
Clarity AI has received widespread recognition for its positive impact and innovative approach, including being selected as a 2020 Technology Pioneer by the World Economic Forum and receiving awards from the Harvard Innovation Lab and funding from Horizon 2020, the European Union’s Research and Innovation program.
Ends
NOTE TO EDITORS
ABOUT CLARITY AI
Clarity AI is a global fintech company that empowers investors to manage the impact of their portfolios through a proprietary technology platform that leverages big data and machine learning to assess sustainability for all societal stakeholders. Founded in 2017 by Rebeca Minguela, Clarity AI has offices in the US, UK and Spain and a client network with over $3T assets under management (AUM). The company has a team of over 100 technology, sustainability and research experts with collective experience from leading organizations, businesses and research institutions including NASA, the World Bank, Google, Netflix, McKinsey & Company, Morgan Stanley, J.P. Morgan, Harvard, M.I.T and more.
Rebeca Minguela is the Founder and CEO of Clarity AI. Previously, she led the Global Digital Transformation Program at Santander Bank after founding and leading Blink Booking, a last-minute hotel booking app acquired by Groupon in 2013, a company she moved to as Senior Director of Product and Technology thereafter. Rebeca has also worked at Bain Capital Private Equity, Boston Consulting Group, German Aerospace Agency, Siemens and IBM. She holds an MBA degree with distinction from Harvard Business School and has won several awards, including Top 25 Women Leaders in Financial Technology in 2019 and 2020, Young Global Leader by the World Economic Forum in 2017 and European Young Leader in 2018.
For more information, visit https://clarity.ai/
ABOUT DEUTSCHE BÖRSE
As an international exchange organisation and innovative market infrastructure provider, Deutsche Börse Group ensures markets characterised by integrity, transparency and stability. With its wide range of products, services and technologies, the Group organises safe and efficient markets for sustainable economies.
Its business areas extend along the entire value chain in exchange trading, including the admission, trading and clearing, and custody of securities and other financial instruments, the dissemination of market data, as well as the management of collateral and liquidity. As a technology company, the Group develops state-of-the-art IT solutions and offers IT systems all over the world.
With around 6,000 employees, the Group has its headquarters in the financial centre of Frankfurt/Rhine-Main, as well as a strong global presence in 38 locations such as Luxembourg, Prague, London, New York, Chicago, Hong Kong, Singapore, Beijing, Tokyo and Sydney.
ABOUT ALMA MUNDI VENTURES
Alma Mundi is a Venture Capital fund investing in B2B tech and Insurtech startups across Europe, the United States and Israel. The investments range from early Seed and Series A, to Series B and later stages. The headquarters are in Madrid and offices in Barcelona, London and Tel Aviv. The portfolio includes startups in London, Paris, Amsterdam, Berlin, Tel Aviv, San Francisco and New York. They bring value to entrepreneurs by leveraging their LPs, leading European insurers, and a global network, called the Mundi Club, which groups more than 750 C-level executives in more than 50 cities worldwide.
1
Gl
obal Asset Management 2018: The Digital Metamorphosis, https://www.bcg.com/publications/2018/global-asset-management-2018-digital-metamorphosis
; Global Sustainable Investment Alliance: 2018 Global Sustainable Investment Review, http://www.gsi-alliance.org/wp-content/uploads/2019/03/GSIR_Review2018.3.28.pdf
2
Har
vard Law School Forum on Corporate Governance: Institutional Investor Survey 2020, https://corpgov.law.harvard.edu/2020/03/25/institutional-investor-survey-2020/
View source version on businesswire.com: https://www.businesswire.com/news/home/20201029005306/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release
Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom